Viking Therapeutics registers Phase 1 trial of obesity candidate VK3019

Viking Therapeutics had one clinical trial update this week, a newly registered early-stage study for its obesity pipeline.

• VK3019, an amylin and calcitonin receptor agonist, is being tested in a Phase 1 trial listed as recruiting. The study is a randomized, double-blind, placebo-controlled single ascending dose study to evaluate safety, tolerability, and pharmacokinetics of VK3019 in overweight and obese adults without comorbidities.¹ The trial plans to enroll approximately 56 participants across seven cohorts of eight participants each, receiving either VK3019 or matching placebo.¹ The study lists an actual start date of 2026-07-06 and an estimated primary completion date of 2026-10-02, with a single site in Lake Forest, California.